GMT is written as "GREENWICH MEAN TIME", the omega replica Royal Greenwich Observatory in hublot replica London, England, focusing on replica watch uk the word "GMT" that symbolizes the pursuit of human civilization for the accuracy of time.Albert refers to the first generation of swiss rolex replica GMT no shoulder pads, gold ring on the surface, and black gold (glossy gilt) is more soft. Interview GMT-MASTER Ref. 1675 for the fake watches uk GMT-MASTER third generation, especially the addition of round mouth shoulder pads, the market value of about 72,000 yuan.

Heraeus invests in Locate Therapeutics

9th May 2014, Hanau, Germany
Precious metal and technology Group, Heraeus Holding (Heraeus), announced today the completion of an equity investment in Nottingham based regenerative medicine platform company, Locate Therapeutics (Locate).

As part of a new strategic initiative to accelerate its product development pipeline Heraeus has been actively seeking enabling technologies and development partners in the burgeoning field of regenerative medicine.

Locate is a specialist regenerative medicine and device company which has been incubated by University of Nottingham. With grant funding and financial assistance from Wellcome Trust and UoN the company has developed TAOS™ a patented platform polymer technology with multiple medical applications. The TAOS (Targeted, Orchestrated Signalling) technology is a world first in tissue repair. It enables the precision focus of therapeutic signals and provides an optimal structure to support tissue repair. Uniquely, TAOS can accommodate and promote the actions of receptor-binding moieties, locally-applied drugs, and emergent biological & cell-based therapies.

Jan Rinnert, Chairman of the Board of Management Heraeus Holding said, “We have been impressed by the scientifically robust way in which Locate has developed and validated TAOS. This is an exciting technology which will enable Heraeus to expand its regenerative medicine pipeline”

Commenting for Locate, Ashley Cooper, CEO said, “We are delighted to have secured an investment from a company that really understands the needs and opportunities that exist in the regenerative medicine field and which is investing for the long term. This gives us great confidence that we will be able to fully exploit the therapeutic and commercial potential of TAOS”.

Founder and CSO of Locate, Professor Kevin Shakesheff, offered an equally upbeat perspective on the investment. “Locate is focussed on clinical problems in which regeneration of human tissue will displace biomaterial or drug therapies in the next decade. With this investment and the continued support of Heraeus we will be able to expedite the commercial development of the most promising and needed regenerative medicine applications of TAOS”.

The financial terms of the investment by Heraeus were not disclosed.


For further information please email info@locatetherapeutics.com or call +44 (0)115 784 0041.

Product Development Pipeline
Application Development
Partnering Opportunities

© 2014 Locate Therapeutics Limited.

All rights reserved.

Registered in England number 04202562.

Locate Therapeutics Limited

MediCity

Thane Road

Beeston

Nottingham NG90 6BH

United Kingdom

 

+44 (0)115 784 0041

info@locatetherapeutics.com

hogan outlet nike air max pas cher louboutin pas cher air jordan pas cher nike air max pas cher air jordan pas cher louboutin pas cher nike air max pas cher louboutin pas cher nike air max pas cher fitflop sandaler udsalg nike air max pas cher fitflop sandaler udsalg nike air max pas cher fitflop sandaler udsalg fitflop sandaler udsalg fitflop sandaler udsalg